KLF4 and breast cancer: In breast cancer stem cells (BCSCs), ZNF217 has been reported to interact with METTL3 and inhibit the m6A methylation of KLF4 and NANOG, which ultimately leads to high expression of KLF4 and NANOG, thus promoting tumorigenesis [74].